Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.62 +0.58%

+$0.04 today

Market cap
$3.04B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.56M

Average 1.66M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$28.63M

FY 2025 · Annual

Investing Cash Flow

-$696,000.00

FY 2025 · Annual

Financing Cash Flow

$11.39M

FY 2025 · Annual

-68.5% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
Deferred Income Tax(1.42M)(1.42M)(1.25M)(2.27M)0
Stock-Based Compensation11.38M12.16M10.72M18.36M22.37M
Change in Working Capital11.85M(35.15M)(6.29M)(8.82M)(10.36M)
Accounts Receivables(13.37M)(13.37M)(8.37M)(1.22M)(10.64M)
Inventory(7.47M)(7.47M)(14.8M)(8.78M)(19.29M)
Accounts Payables(4.32M)(4.32M)6.96M(9.61M)(69K)
Other Working Capital19.98M(9.99M)9.92M10.79M19.63M
Other Non-Cash Items3.5M3.52M(1.1M)(2.05M)3.91M
Operating Cash Flow(102.89M)(102.89M)(47.02M)(36.98M)28.63M
Capital Expenditures(524K)(524K)(2.26M)(868K)(696K)
Acquisitions (Net)38.47M0000
Purchases of Investments(43.02M)0(43.74M)(34.49M)0
Sales of Investments34.99M34.99M40M40.24M0
Other Investing Activities4.55M0000
Investing Cash Flow34.46M34.46M(6M)4.88M(696K)
Debt Repayment0102.72M038.17M9.17M
Common Stock Issued27M30M581K013.1M
Common Stock Repurchased(534K)(468K)(1.01M)(3.73M)(10.88M)
Dividends Paid00000
Other Financing Activities0(4.78M)(604K)1.73M0
Financing Cash Flow27.25M127.47M(1.61M)36.17M11.39M
Effect of Forex Changes(3K)(4.35M)000
Net Change in Cash59.04M59.04M(54.64M)4.07M39.32M
Free Cash Flow(103.42M)(103.42M)(49.29M)(37.85M)27.93M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$554.0K
+ D&A$12.2M
+ Stock-Based Comp$22.4M
+ Deferred Tax$0
- Working Capital-$10.4M
+ Other Non-Cash$3.9M
= Operating Cash Flow$28.6M
- Capex-$696.0K
= Free Cash Flow$27.9M

Analysis

FY2025 free cash flow is $27.9M. FCF conversion is 5041.5% of net income. Operating cash flow was $28.6M, with capex of -$696.0K. The largest bridge item is Stock-Based Comp at $22.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 6, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipNov 4, 2026

Does XERS generate free cash flow?

Xeris Biopharma Holdings, Inc. (XERS) generated $27.93M of free cash flow in fiscal 2025.

How much operating cash flow does XERS produce?

Operating cash flow was $28.63M, before capital expenditures of $696,000.00.